Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–98. https://doi.org/10.1038/s41574-019-0176-8.

Article  PubMed  Google Scholar 

Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10. https://doi.org/10.1016/j.metabol.2018.09.005.

Article  PubMed  CAS  Google Scholar 

World Health Organization. Obesity and overweight; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 23 Nov 2022.

Atawia RT, Bunch KL, Toque HA, Caldwell RB, Caldwell RW. Mechanisms of obesity-induced metabolic and vascular dysfunctions. Front Biosci. 2019;24:890–934. https://doi.org/10.2741/4758.

Article  Google Scholar 

Martyn JA, Kaneki M, Yasuhara S. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology. 2008;109:137–48. https://doi.org/10.1097/ALN.0b013e3181799d45.

Article  PubMed  Google Scholar 

Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006;116:1756–60. https://doi.org/10.1172/jci29189.

Article  PubMed  PubMed Central  CAS  Google Scholar 

World Health Organization. Obesity-complications; 2022. Available from: https://www.who.int/health-topics/obesity#tab=tab_2. Accessed 23 Nov 2022.

International Diabetes Federation. Diabetes atlas, 10 edn. Brussels: International Diabetes Federation; 2021. Available from: https://diabetesatlas.org/atlas/tenth-edition/. Accessed 23 Nov 2022.

World Health Organization. Diabetes; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 23 Nov 2022.

Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother. 2018;107:306–28. https://doi.org/10.1016/j.biopha.2018.07.157.

Article  PubMed  CAS  Google Scholar 

Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88:1322–35. https://doi.org/10.2522/ptj.20080008.

Article  PubMed  PubMed Central  Google Scholar 

International Diabetes Federation. Diabetes complications; 2020. Available from: https://www.idf.org/aboutdiabetes/complications.html. Accessed 23 Nov 2022.

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018 — a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701. https://doi.org/10.2337/dci18-0033.

Article  PubMed  PubMed Central  Google Scholar 

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85. https://doi.org/10.2337/dc10-0666.

Article  PubMed  PubMed Central  Google Scholar 

Wojciechowska J, Krajewski W, Bolanowski M, Kręcicki T, Zatoński T. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124:263–75. https://doi.org/10.1055/s-0042-100910.

Article  PubMed  CAS  Google Scholar 

Zelenko Z, Gallagher EJ. Diabetes and cancer. Endocrinol Metab Clin North Am. 2014;43:167–85. https://doi.org/10.1016/j.ecl.2013.09.008.

Article  PubMed  Google Scholar 

Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and insulin analogs and risk of cancer — systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013;8:333–48. https://doi.org/10.2174/15680266113136660067.

Article  PubMed  CAS  Google Scholar 

Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, et al. Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales. Front Pharmacol. 2021;12:807548. https://doi.org/10.3389/fphar.2021.807548 (An updated review of currently available antihyperglycemic pharmacotherapies and future developments.).

Article  PubMed  CAS  Google Scholar 

Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes. 2014;4: e143. https://doi.org/10.1038/nutd.2014.40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Srivastava SP, Goodwin JE. Cancer biology and prevention in diabetes. Cells. 2020;9(6):1380. https://doi.org/10.3390/cells9061380 (A review of our understanding of the mechanistic links between diabetes and cancer.).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alsaggaf R, Pfeiffer RM, Wang Y, St George DMM, Zhan M, Wagner KR, et al. Diabetes, metformin and cancer risk in myotonic dystrophy type I. Int J Cancer. 2020;147:785–92. https://doi.org/10.1002/ijc.32801 (A case-control study in more than 13,000 people demonstrating that diabetes confers increased cancer risk in patients with myotonic dystrophy type I but this increase is abolished among those treated with metformin.).

Article  PubMed  CAS  Google Scholar 

Wang Z, Bao C, Su C, Xu W, Luo H, Chen L, et al. Association between diabetes or antidiabetic therapy and lung cancer: a meta-analysis. J Diabetes Investig. 2013;4:659–66. https://doi.org/10.1111/jdi.12112.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–5. https://doi.org/10.1136/bmj.38415.708634.F7.

Article  PubMed  PubMed Central  Google Scholar 

Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–8. https://doi.org/10.2337/diacare.29.02.06.dc05-1558.

Article  PubMed  Google Scholar 

Zhang K, Bai P, Dai H, Deng Z. Metformin and risk of cancer among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Prim Care Diabetes. 2021;15:52–8. https://doi.org/10.1016/j.pcd.2020.06.001 (A recent systematic review with meta-analysis of 67 studies with more than 10 million patients with diabetes, demonstrating that (i) those who have ever used metformin have 30% lower risk than those who have never used metofrmin, and (ii) metformin is associated with 20% lower risk compared with other antidiabetic medications.).

Article  PubMed  Google Scholar 

Ng CW, Jiang AA, Toh EMS, Ng CH, Ong ZH, Peng S, et al. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. Int J Colorectal Dis. 2020;35:1501–12. https://doi.org/10.1007/s00384-020-03676-x (A recent systematic review with meta-analysis of 58 studies in about 1.8 million patients with type 2 diabetes showing that metformin use is associated with reduced incidence of, and improved survival from, colorectal cancer.).

Article  PubMed  Google Scholar 

Farmer RE, Ford D, Forbes HJ, Chaturvedi N, Kaplan R, Smeeth L, et al. Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation. Int J Epidemiol. 2017;46:728–44. https://doi.org/10.1093/ije/dyw275.

Article  PubMed  Google Scholar 

Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE. 2013;8:e71583. https://doi.org/10.1371/journal.pone.0071583.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dowling RJO, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells. Cancer Res. 2007;67:10804–12. https://doi.org/10.1158/0008-5472.Can-07-2310.

Article  PubMed  CAS  Google Scholar 

Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, DePinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6. https://doi.org/10.1126/science.1120781.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shackelford DB, Shaw RJ. The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–75. https://doi.org/10.1038/nrc2676.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–85. https://doi.org/10.1007/s00125-017-4342-z.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Sci Rep. 2015;5:10147. https://doi.org/10.1038/srep10147.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tseng YH, Tsan YT, Chan WC, Sheu WH, Chen PC. Use of an alpha-glucosidase inhibitor and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based cohort study. Diabetes Care. 2015;38:2068–74. https://doi.org/10.2337/dc15-0563.

Article  PubMed  CAS  Google Scholar 

Valent F. Diabetes mellitus and cancer of the digestive organs: an Italian population-based cohort study. J Diabetes Complicat. 2015;29:1056–61. https://doi.org/10.1016/j.jdiacomp.2015.07.017.

Article  Google Scholar 

Zhao Y, Wang Y, Lou H, Shan L. Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Oncotarget. 2017;8:81027–39. https://doi.org/10.18632/oncotarget.17515.

Article  PubMed  PubMed Central  Google Scholar 

Chen YL, Cheng KC, Lai SW, Tsai IJ, Lin CC, Sung FC, et al. Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan. Gastric Cancer. 2013;16:389–96. https://doi.org/10.1007/s10120-012-0197-7.

Article  PubMed  Google Scholar 

Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer. 2012;13:143–8. https://doi.org/10.1016/j.cllc.2011.10.002.

Article  PubMed  CAS  Google Scholar 

Lin CM, Huang HL, Chu FY, Fan HC, Chen HA, Chu DM, et al. Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study. PLoS ONE. 2015;10: e0125421. https://doi.org/10.1371/journal.pone.0125421.

Article